Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Inhibition of phosphodiesterase-4 decreases ethanol intake in mice.

Hu W, Lu T, Chen A, Huang Y, Hansen R, Chandler LJ, Zhang HT.

Psychopharmacology (Berl). 2011 Nov;218(2):331-9. doi: 10.1007/s00213-011-2290-8.

2.

The phosphodiesterase-4 (PDE4) inhibitor rolipram decreases ethanol seeking and consumption in alcohol-preferring Fawn-Hooded rats.

Wen RT, Zhang M, Qin WJ, Liu Q, Wang WP, Lawrence AJ, Zhang HT, Liang JH.

Alcohol Clin Exp Res. 2012 Dec;36(12):2157-67. doi: 10.1111/j.1530-0277.2012.01845.x.

3.

Reduction of alcohol drinking of alcohol-preferring (P) and high-alcohol drinking (HAD1) rats by targeting phosphodiesterase-4 (PDE4).

Franklin KM, Hauser SR, Lasek AW, McClintick J, Ding ZM, McBride WJ, Bell RL.

Psychopharmacology (Berl). 2015 Jul;232(13):2251-62. doi: 10.1007/s00213-014-3852-3.

4.

Role of phosphodiesterase-4 on ethanol elicited locomotion and narcosis.

Baliño P, Ledesma JC, Aragon CM.

Neuropharmacology. 2016 Feb;101:271-8. doi: 10.1016/j.neuropharm.2015.10.001.

PMID:
26449868
5.

BK channel-mediated relaxation of urinary bladder smooth muscle: a novel paradigm for phosphodiesterase type 4 regulation of bladder function.

Xin W, Li N, Cheng Q, Petkov GV.

J Pharmacol Exp Ther. 2014 Apr;349(1):56-65. doi: 10.1124/jpet.113.210708.

7.

Inhibition of phosphodiesterase 4 reduces ethanol intake and preference in C57BL/6J mice.

Blednov YA, Benavidez JM, Black M, Harris RA.

Front Neurosci. 2014 May 27;8:129. doi: 10.3389/fnins.2014.00129.

8.

Powerful relaxation of phosphodiesterase type 4 inhibitor rolipram in the pig and human bladder neck.

Ribeiro AS, Fernandes VS, Martínez-Sáenz A, Martínez P, Barahona MV, Orensanz LM, Blaha I, Serrano-Margüello D, Bustamante S, Carballido J, García-Sacristán A, Prieto D, Hernández M.

J Sex Med. 2014 Apr;11(4):930-41. doi: 10.1111/jsm.12456.

PMID:
24754330
9.

The involvement of type IV phosphodiesterases in cocaine-induced sensitization and subsequent pERK expression in the mouse nucleus accumbens.

Janes AC, Kantak KM, Cherry JA.

Psychopharmacology (Berl). 2009 Oct;206(2):177-85. doi: 10.1007/s00213-009-1594-4.

PMID:
19588125
10.

PET measurements of cAMP-mediated phosphodiesterase-4 with (R)-[11C]rolipram.

Kenk M, Thomas A, Lortie M, Dekemp R, Beanlands RS, Dasilva JN.

Curr Radiopharm. 2011 Jan;4(1):44-58. Review.

PMID:
22191614
11.

Short-term or long-term treatments with a phosphodiesterase-4 (PDE4) inhibitor result in opposing agonist-induced Ca(2+) responses in endothelial cells.

Campos-Toimil M, Keravis T, Orallo F, Takeda K, Lugnier C.

Br J Pharmacol. 2008 May;154(1):82-92. doi: 10.1038/bjp.2008.56.

12.
13.

Spatiotemporal dynamics of beta-adrenergic cAMP signals and L-type Ca2+ channel regulation in adult rat ventricular myocytes: role of phosphodiesterases.

Leroy J, Abi-Gerges A, Nikolaev VO, Richter W, Lechêne P, Mazet JL, Conti M, Fischmeister R, Vandecasteele G.

Circ Res. 2008 May 9;102(9):1091-100. doi: 10.1161/CIRCRESAHA.107.167817.

14.

Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity.

Kanes SJ, Tokarczyk J, Siegel SJ, Bilker W, Abel T, Kelly MP.

Neuroscience. 2007 Jan 5;144(1):239-46.

15.

Effects of cAMP-dependent protein kinase activator and inhibitor on in vivo rolipram binding to phosphodiesterase 4 in conscious rats.

Itoh T, Abe K, Hong J, Inoue O, Pike VW, Innis RB, Fujita M.

Synapse. 2010 Feb;64(2):172-6. doi: 10.1002/syn.20728.

16.

The therapeutic profile of rolipram, PDE target and mechanism of action as a neuroprotectant following spinal cord injury.

Schaal SM, Garg MS, Ghosh M, Lovera L, Lopez M, Patel M, Louro J, Patel S, Tuesta L, Chan WM, Pearse DD.

PLoS One. 2012;7(9):e43634. doi: 10.1371/journal.pone.0043634.

17.

Discriminative stimulus effects of the type-4 phosphodiesterase inhibitor rolipram in rats.

Makhay MM, Houslay MD, O'Donnell JM.

Psychopharmacology (Berl). 2001 Nov;158(3):297-304.

PMID:
11713620
18.

Interaction between the antidepressant-like behavioral effects of beta adrenergic agonists and the cyclic AMP PDE inhibitor rolipram in rats.

Zhang HT, Huang Y, Mishler K, Roerig SC, O'Donnell JM.

Psychopharmacology (Berl). 2005 Oct;182(1):104-15.

PMID:
16010541
19.

Phosphodiesterase 4 inhibition enhances the dopamine D1 receptor/PKA/DARPP-32 signaling cascade in frontal cortex.

Kuroiwa M, Snyder GL, Shuto T, Fukuda A, Yanagawa Y, Benavides DR, Nairn AC, Bibb JA, Greengard P, Nishi A.

Psychopharmacology (Berl). 2012 Feb;219(4):1065-79. doi: 10.1007/s00213-011-2436-8.

Items per page

Supplemental Content

Support Center